Prior studies have compared ocular inflammation in patients treated with intravitreal anti-VEGF for various exudative eye diseases (e.g., non-proliferative diabetic retinopathy, macular edema with branch or central retinal vein occlusion). Here, VEGFA is linked to eye disorder.